Josh Schimmer
Stock Analyst at Cantor Fitzgerald
(4.35)
# 318
Out of 5,169 analysts
142
Total ratings
53.73%
Success rate
15.81%
Average return
Main Sectors:
Stocks Rated by Josh Schimmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Maintains: Overweight | $8 → $10 | $4.47 | +123.71% | 8 | Feb 27, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $135 → $140 | $97.43 | +43.69% | 2 | Feb 27, 2026 | |
| JANX Janux Therapeutics | Maintains: Overweight | $150 → $100 | $13.86 | +621.50% | 8 | Feb 27, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $130 | $91.66 | +41.83% | 7 | Dec 8, 2025 | |
| DMAC DiaMedica Therapeutics | Initiates: Overweight | $25 | $7.12 | +251.12% | 1 | Nov 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Overweight | $120 → $200 | $114.23 | +75.09% | 1 | Nov 6, 2025 | |
| CABA Cabaletta Bio | Maintains: Overweight | $15 → $30 | $2.97 | +910.10% | 3 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $100 → $110 | $70.12 | +56.87% | 13 | Oct 30, 2025 | |
| IVVD Invivyd | Initiates: Overweight | $10 | $1.51 | +562.25% | 1 | Oct 6, 2025 | |
| CGON CG Oncology | Reiterates: Overweight | $75 | $64.45 | +16.37% | 5 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $20.06 | - | 3 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $24.11 | +3.69% | 4 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $10.69 | +133.86% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $11 → $6 | $5.88 | +2.04% | 2 | Jun 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $260 → $280 | $227.41 | +23.13% | 4 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $4.88 | +924.59% | 2 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $20 | $5.80 | +244.83% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $250.83 | -14.28% | 5 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $5 | $2.46 | +103.25% | 4 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.99 | - | 5 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.30 | +261.45% | 4 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.56 | - | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.05 | - | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $90 | $36.05 | +149.65% | 6 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.22 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $142.70 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $56.71 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.55 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.42 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $114.51 | - | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $9.36 | +1,182.05% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $55.07 | +18.03% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $11 | $13.50 | -18.52% | 2 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $140 → $130 | $130.71 | -0.54% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | $760 | $744.12 | +2.13% | 2 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $23.45 | -36.03% | 1 | Mar 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $13.13 | +318.89% | 1 | Feb 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $1.79 | +1,575.98% | 1 | Dec 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $1.18 | - | 4 | Dec 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.28 | - | 3 | Feb 25, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $222 → $250 | $442.00 | -43.44% | 4 | Nov 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $92.24 | - | 2 | Jun 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $71.67 | - | 2 | May 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: In-Line | n/a | $3.76 | - | 2 | Mar 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $14.73 | +49.36% | 1 | Nov 7, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.83 | - | 2 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $55.43 | - | 1 | Aug 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $95 | $208.34 | -54.40% | 1 | Aug 17, 2017 |
Rocket Pharmaceuticals
Feb 27, 2026
Maintains: Overweight
Price Target: $8 → $10
Current: $4.47
Upside: +123.71%
Nuvalent
Feb 27, 2026
Maintains: Overweight
Price Target: $135 → $140
Current: $97.43
Upside: +43.69%
Janux Therapeutics
Feb 27, 2026
Maintains: Overweight
Price Target: $150 → $100
Current: $13.86
Upside: +621.50%
Mirum Pharmaceuticals
Dec 8, 2025
Maintains: Overweight
Price Target: $95 → $130
Current: $91.66
Upside: +41.83%
DiaMedica Therapeutics
Nov 14, 2025
Initiates: Overweight
Price Target: $25
Current: $7.12
Upside: +251.12%
Palvella Therapeutics
Nov 6, 2025
Maintains: Overweight
Price Target: $120 → $200
Current: $114.23
Upside: +75.09%
Cabaletta Bio
Oct 31, 2025
Maintains: Overweight
Price Target: $15 → $30
Current: $2.97
Upside: +910.10%
BridgeBio Pharma
Oct 30, 2025
Maintains: Overweight
Price Target: $100 → $110
Current: $70.12
Upside: +56.87%
Invivyd
Oct 6, 2025
Initiates: Overweight
Price Target: $10
Current: $1.51
Upside: +562.25%
CG Oncology
Sep 8, 2025
Reiterates: Overweight
Price Target: $75
Current: $64.45
Upside: +16.37%
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.06
Upside: -
Sep 5, 2025
Reiterates: Overweight
Price Target: $25
Current: $24.11
Upside: +3.69%
Jul 1, 2025
Initiates: Overweight
Price Target: $25
Current: $10.69
Upside: +133.86%
Jun 23, 2025
Downgrades: In-Line
Price Target: $11 → $6
Current: $5.88
Upside: +2.04%
May 2, 2025
Maintains: Outperform
Price Target: $260 → $280
Current: $227.41
Upside: +23.13%
Apr 1, 2025
Reiterates: Overweight
Price Target: $50
Current: $4.88
Upside: +924.59%
Mar 25, 2025
Maintains: Overweight
Price Target: $23 → $20
Current: $5.80
Upside: +244.83%
Feb 20, 2025
Reiterates: Overweight
Price Target: $215
Current: $250.83
Upside: -14.28%
Dec 20, 2024
Downgrades: In-Line
Price Target: $5
Current: $2.46
Upside: +103.25%
Dec 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.99
Upside: -
Oct 8, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.30
Upside: +261.45%
Sep 23, 2024
Downgrades: Neutral
Price Target: n/a
Current: $8.56
Upside: -
Sep 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.05
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $90
Current: $36.05
Upside: +149.65%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.22
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $142.70
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $56.71
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.55
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.42
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $114.51
Upside: -
Aug 26, 2024
Maintains: Outperform
Price Target: $120
Current: $9.36
Upside: +1,182.05%
Aug 9, 2024
Reiterates: Overweight
Price Target: $65
Current: $55.07
Upside: +18.03%
Jun 6, 2023
Maintains: Outperform
Price Target: $20 → $11
Current: $13.50
Upside: -18.52%
Nov 14, 2022
Downgrades: In-Line
Price Target: $140 → $130
Current: $130.71
Upside: -0.54%
Oct 17, 2022
Downgrades: In-Line
Price Target: $760
Current: $744.12
Upside: +2.13%
Mar 15, 2022
Initiates: Outperform
Price Target: $15
Current: $23.45
Upside: -36.03%
Feb 2, 2021
Initiates: Outperform
Price Target: $55
Current: $13.13
Upside: +318.89%
Dec 29, 2020
Initiates: Outperform
Price Target: $30
Current: $1.79
Upside: +1,575.98%
Dec 9, 2019
Downgrades: In-Line
Price Target: n/a
Current: $1.18
Upside: -
Feb 25, 2019
Upgrades: Outperform
Price Target: n/a
Current: $8.28
Upside: -
Nov 16, 2018
Upgrades: Outperform
Price Target: $222 → $250
Current: $442.00
Upside: -43.44%
Jun 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $92.24
Upside: -
May 8, 2018
Downgrades: In-Line
Price Target: n/a
Current: $71.67
Upside: -
Mar 12, 2018
Downgrades: In-Line
Price Target: n/a
Current: $3.76
Upside: -
Nov 7, 2017
Initiates: Outperform
Price Target: $22
Current: $14.73
Upside: +49.36%
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $13.83
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: n/a
Current: $55.43
Upside: -
Aug 17, 2017
Initiates: Outperform
Price Target: $95
Current: $208.34
Upside: -54.40%